Ifosfamide: Clinical Trials

70 trials of Ifosfamide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

39 completed, 10 terminated, 7 unknown, 5 recruiting. 70 Phase 1, 38 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 170Completed 39, Terminated 10, Unknown 7, Recruiting 5, Withdrawn 5, Active not recruiting 3, Not yet recruiting 1
Phase 238Completed 21, Recruiting 4, Unknown 4, Terminated 3, Withdrawn 3, Active not recruiting 2, Not yet recruiting 1

Follow Ifosfamide: new trials by email Literature Review of Ifosfamide trials Research Report on Ifosfamide

Trials (filtered) newest first · largest first

All 70 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Vincristine, Doxorubicin, Cyclophosphamide - Metastatic Ewing Sarcoma
Phase 1RecruitingH. Lee Moffitt Cancer Center and Research Institute152026-02-052026-09-25
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma
Selinexor - B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory
Phase 1 / Phase 2RecruitingSamsung Medical Center372024-05-012026-04-23
NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma
Phase 1 / Phase 2RecruitingSt. Jude Children's Research Hospital1392024-03-272026-08-03
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
ADI PEG20, Ifosfamide, Radiotherapy - Soft Tissue Sarcoma, Sts
Phase 1TerminatedWashington University School of Medicine62024-03-142026-09-03
Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
BEBT-908 for Injection, Rituximab Injection, Gemcitabine Hydrochloride for Injection - Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 1UnknownBeBetter Med Inc752023-12-012023-12-11
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma
Sulfatinib, Etoposide, Isophosphamide - Osteosarcoma
Phase 1 / Phase 2Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine1482023-01-012022-10-21
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Obinutuzumab, Glofitamab, Rituximab - Mature B-Cell Non-Hodgkin Lymphoma
Phase 1 / Phase 2RecruitingHoffmann-La Roche652022-11-162026-11-05
A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma
Glofitamab, Obinutuzumab, Tocilizumab - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 1CompletedHoffmann-La Roche432022-11-042025-12-01
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Phase 1 / Phase 2Active not recruitingGenmab5432020-11-032026-11-03
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
Irinotecan, Actinomycin D, Doxorubicin - Rhabdomyosarcoma
Phase 1 / Phase 2RecruitingUniversity of Birmingham16722020-09-172024-05-23
Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
Famitinib, Ifosfamide, Camrelizumab - Effect of Drugs, Progression
Phase 1 / Phase 2WithdrawnPeking University People's Hospital2019-08-152020-05-19
Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
Idelalisib, Rituximab, Ifosfamide - Diffuse Large B-Cell Lymphoma, Mediastinal B-cell Lymphoma
Phase 1WithdrawnGilead Sciences2019-06-012018-12-11
Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors
Pazopanib, Ifosfamide, Carboplatin - Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor
Phase 1 / Phase 2UnknownSamsung Medical Center462018-10-012018-09-19
Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
Autologous Hematopoietic Stem Cell Transplantation, Avelumab, Carboplatin - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma
Phase 1CompletedCity of Hope Medical Center162018-06-082026-10-02
A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Olaratumab, Doxorubicin, Ifosfamide - Soft Tissue Sarcoma
Phase 1CompletedEli Lilly and Company242017-10-182020-09-10
Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Venetoclax, Rituximab, Ifosfamide - Diffuse Large B-cell-lymphoma
Phase 1 / Phase 2Active not recruitingMolly Gallogly652017-06-262022-11-16
Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas
Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Nivolumab 100 MG/10 ML [Opdivo], Epirubicin - Soft Tissue Sarcoma, Bone Sarcoma
Phase 1 / Phase 2CompletedGrupo Espanol de Investigacion en Sarcomas1972017-05-312024-08-13
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
MASCT-I, Ifosfamide, PD1 antibody - Advanced Solid Tumors
Phase 1TerminatedHRYZ Biotech Co.1052017-02-222025-07-24
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)
Parsaclisib, Itacitinib, Rituximab - B-Cell Malignancies
Phase 1 / Phase 2CompletedIncyte Corporation882016-09-222023-09-28
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Olaratumab, Doxorubicin, Vincristine - Neoplasm Metastasis
Phase 1CompletedEli Lilly and Company682016-08-292020-05-20

Showing 20 of 70. Sign in to see all of them.

Conditions studied

Lymphoma, Large B-Cell, Diffuse (17)  ·  Sarcoma (13)  ·  Lymphoma (10)  ·  Osteosarcoma (9)  ·  Hodgkin Disease (8)  ·  Lymphoma, Follicular (6)  ·  Lymphoma, Mantle-Cell (6)  ·  Lymphoma, Non-Hodgkin (6)  ·  Testicular Neoplasms (6)  ·  Burkitt Lymphoma (5)  ·  Lymphoma, Large-Cell, Anaplastic (5)  ·  Neoplasms (5)  ·  Ovarian Neoplasms (5)  ·  Testicular Germ Cell Tumor (5)  ·  Carcinoma, Renal Cell (4)

Sponsors

Memorial Sloan Kettering Cancer Center (6)  ·  M.D. Anderson Cancer Center (5)  ·  National Cancer Institute (NCI) (4)  ·  City of Hope Medical Center (3)  ·  Children's Oncology Group (2)  ·  Eli Lilly and Company (2)  ·  Hoffmann-La Roche (2)  ·  Samsung Medical Center (2)  ·  St. Jude Children's Research Hospital (2)  ·  University of Washington (2)  ·  AIDS Malignancy Consortium (1)  ·  Academic and Community Cancer Research United (1)  ·  Alaunos Therapeutics (1)  ·  Armando Santoro, MD (1)  ·  BeBetter Med Inc (1)

Countries

United States (51)  ·  Italy (9)  ·  France (7)  ·  Spain (6)  ·  United Kingdom (6)  ·  Australia (5)  ·  China (5)  ·  Germany (5)  ·  South Korea (5)  ·  Denmark (4)  ·  Belgium (3)  ·  Canada (3)  ·  Czechia (3)  ·  Netherlands (3)  ·  Israel (2)

Top investigators

Armando Santoro, MD (2)  ·  Sonali Smith (2)  ·  Ajay Gopal (1)  ·  Alba Rubio (1)  ·  Andres Morales, MD (1)  ·  Antonio Casado (1)  ·  Aspasia Stamatoullas Bastard, MD (1)  ·  Benjamin B. Weinberger, MD (1)  ·  Binhao Li, PhD (1)  ·  Burton L. Eisenberg, MD (1)

Results publications

PMID 31401903, PMID 15814645, PMID 17194908, PMID 19636012, PMID 19994492, PMID 20194867, PMID 23664013, PMID 29226797, PMID 29386196, PMID 29622656, PMID 30518502, PMID 30573564, PMID 30803990, PMID 33035333, PMID 33203665, PMID 33334730, PMID 34296427, PMID 34310745, PMID 34329577, PMID 34416158, PMID 34416160, PMID 34493319, PMID 34515338, PMID 34562750, PMID 35975738, PMID 36821768, PMID 37632592, PMID 38635762, PMID 39240498, PMID 39356980, PMID 39792928, PMID 40920572, PMID 41784015, PMID 41836677, PMID 42545754, PMID 42622258, PMID 42660129

NIH funding

P30CA008748 (2), P30CA033572 (2), 2015 (1), 2016 (1), 2017 (1), 2018 (1), 2023 (1), N01CM62201 (1), P30CA015083 (1), P30CA015704 (1), P30CA016672 (1), P30CA069533 (1), R01CA136907 (1), U01CA069852 (1), U01CA121947 (1)